JP2019537600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537600A5 JP2019537600A5 JP2019523763A JP2019523763A JP2019537600A5 JP 2019537600 A5 JP2019537600 A5 JP 2019537600A5 JP 2019523763 A JP2019523763 A JP 2019523763A JP 2019523763 A JP2019523763 A JP 2019523763A JP 2019537600 A5 JP2019537600 A5 JP 2019537600A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- seq
- peg
- poly
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 44
- 239000002105 nanoparticle Substances 0.000 claims description 43
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 24
- 150000001413 amino acids Chemical group 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 22
- 229920001223 polyethylene glycol Polymers 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000002091 cationic group Chemical group 0.000 claims description 14
- 229920000359 diblock copolymer Polymers 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 229920003046 tetrablock copolymer Polymers 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- -1 citalabine Chemical compound 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 6
- 108010011110 polyarginine Proteins 0.000 claims description 6
- 241001455273 Tetrapoda Species 0.000 claims description 5
- 229920001400 block copolymer Polymers 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- NMNDQBZTIMGTSF-UHFFFAOYSA-N 11h-indeno[1,2-h]isoquinoline Chemical compound C1=CN=CC2=C3CC4=CC=CC=C4C3=CC=C21 NMNDQBZTIMGTSF-UHFFFAOYSA-N 0.000 claims description 4
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229960003603 decitabine Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims description 4
- 229960004768 irinotecan Drugs 0.000 claims description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 4
- 229960001756 oxaliplatin Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229950007866 tanespimycin Drugs 0.000 claims description 4
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229940063683 taxotere Drugs 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960001467 bortezomib Drugs 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010055114 Colon cancer metastatic Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000012239 Developmental disease Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000030172 endocrine system disease Diseases 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229920000428 triblock copolymer Polymers 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022193548A JP2023014340A (ja) | 2016-11-02 | 2022-12-02 | ポリマーナノ粒子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416574P | 2016-11-02 | 2016-11-02 | |
| US62/416,574 | 2016-11-02 | ||
| PCT/US2017/059542 WO2018085407A1 (en) | 2016-11-02 | 2017-11-01 | Polymeric nanoparticles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193548A Division JP2023014340A (ja) | 2016-11-02 | 2022-12-02 | ポリマーナノ粒子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537600A JP2019537600A (ja) | 2019-12-26 |
| JP2019537600A5 true JP2019537600A5 (OSRAM) | 2020-11-12 |
Family
ID=62076348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523763A Pending JP2019537600A (ja) | 2016-11-02 | 2017-11-01 | ポリマーナノ粒子 |
| JP2022193548A Pending JP2023014340A (ja) | 2016-11-02 | 2022-12-02 | ポリマーナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193548A Pending JP2023014340A (ja) | 2016-11-02 | 2022-12-02 | ポリマーナノ粒子 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11484507B2 (OSRAM) |
| EP (1) | EP3534909A4 (OSRAM) |
| JP (2) | JP2019537600A (OSRAM) |
| KR (1) | KR20190082263A (OSRAM) |
| CN (1) | CN110114072A (OSRAM) |
| WO (1) | WO2018085407A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019013255A1 (ja) * | 2017-07-11 | 2019-01-17 | 学校法人東京薬科大学 | 核酸送達用組成物及び核酸含有組成物 |
| US20210030692A1 (en) * | 2018-01-29 | 2021-02-04 | The Johns Hopkins University | Polymeric nanoparticle compositions for encapsulation and sustained release of protein therapeutics |
| AU2021300174A1 (en) * | 2020-06-30 | 2023-01-19 | Tharimmune, Inc. | Nanoparticles and methods of manufacture thereof |
| WO2022251844A1 (en) * | 2021-05-25 | 2022-12-01 | Hillstream Biopharma, Inc. | Polymeric nanoparticles comprising chemotherapeutic compounds and related methods |
| WO2023034605A1 (en) * | 2021-09-03 | 2023-03-09 | Hillstream Biopharma, Inc. | Polymeric nanoparticles comprising a histone deacetylase 6 / phosphoinositide 3-kinase-8 dual inhibitor and related methods |
| ES3035530T3 (en) | 2023-03-09 | 2025-09-04 | Minneamrita Therapeutics Llc | Drug combination for the treatment of stomach cancer |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244823B2 (en) * | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
| AU4541101A (en) | 2000-03-02 | 2001-09-12 | Xencor Inc | Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| FR2822156A1 (fr) * | 2001-03-16 | 2002-09-20 | Centre Nat Rech Scient | Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications |
| WO2003086369A2 (en) | 2002-04-05 | 2003-10-23 | Valorisation-Recherche, Societe En Commandite | Stealthy polymeric biodegradable nanospheres and uses thereof |
| US20080299205A1 (en) | 2004-07-19 | 2008-12-04 | Mayer Lawrence D | Particulate Constructs For Release of Active Agents |
| US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| EP2046575A4 (en) | 2006-07-28 | 2010-01-13 | Bridgestone Corp | POLYMERS CORE SHELL NANOPARTICLES WITH AN INTERPHASE AREA |
| US20080081075A1 (en) | 2006-10-02 | 2008-04-03 | National Tsing Hua University | Multifunctional mixed micelle of graft and block copolymers and preparation thereof |
| WO2008124639A2 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
| US20100129456A1 (en) | 2007-05-14 | 2010-05-27 | Ltt Bio-Pharma Co., Ltd. | Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group |
| BRPI0817664A2 (pt) * | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
| JP4824710B2 (ja) | 2008-02-08 | 2011-11-30 | 国立清華大学 | グラフト共重合体およびブロック共重合体の多機能混合ミセルならびにその製造方法 |
| CN101932311B (zh) | 2008-02-22 | 2014-07-16 | 东丽株式会社 | 微粒及其药物组合物 |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| CN102000340B (zh) | 2009-09-11 | 2012-10-31 | 江西科技师范学院 | 一种靶向性高分子药物载体及制备方法和应用 |
| WO2011115819A2 (en) | 2010-03-15 | 2011-09-22 | Genus Oncology, Llc | Small molecule inhibitors of muc1 and methods of identifying the same |
| BR112012025568A2 (pt) | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
| US20120052097A1 (en) | 2010-08-20 | 2012-03-01 | Cerulean Pharma Inc. | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
| AR084210A1 (es) | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
| JP6100762B2 (ja) * | 2011-06-02 | 2017-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 膜で被包されたナノ粒子および使用方法 |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| CN102276813B (zh) | 2011-08-19 | 2013-01-16 | 江西科技师范学院 | 含叶酸靶向高分子药物载体及其制备方法 |
| CN104093739A (zh) * | 2011-10-24 | 2014-10-08 | 艾伯维公司 | 针对tnf的免疫结合剂 |
| US9149426B2 (en) | 2012-02-15 | 2015-10-06 | University Of Tennessee Research Foundation | Nanoparticle composition and methods to make and use the same |
| EP3939572B1 (en) * | 2012-04-12 | 2024-03-27 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
| EP3778696A1 (en) * | 2012-04-23 | 2021-02-17 | NanoProteagen Ltd. | Polymeric nanoparticles and a process of preparation thereof |
| WO2014053882A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| BR112015021970A2 (pt) * | 2013-03-14 | 2017-07-18 | Massachusetts Inst Technology | composições à base de nanopartículas |
-
2017
- 2017-11-01 JP JP2019523763A patent/JP2019537600A/ja active Pending
- 2017-11-01 EP EP17868431.2A patent/EP3534909A4/en active Pending
- 2017-11-01 CN CN201780080722.4A patent/CN110114072A/zh active Pending
- 2017-11-01 KR KR1020197015816A patent/KR20190082263A/ko not_active Ceased
- 2017-11-01 US US16/466,566 patent/US11484507B2/en active Active
- 2017-11-01 WO PCT/US2017/059542 patent/WO2018085407A1/en not_active Ceased
-
2022
- 2022-10-06 US US17/938,369 patent/US20230157969A1/en active Pending
- 2022-12-02 JP JP2022193548A patent/JP2023014340A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537600A5 (OSRAM) | ||
| Afsharzadeh et al. | Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment | |
| Doppalapudi et al. | Biodegradable polymers for targeted delivery of anti-cancer drugs | |
| Wu et al. | Nanogel‐incorporated physical and chemical hybrid gels for highly effective chemo–protein combination therapy | |
| Barzegar Behrooz et al. | Smart bomb AS 1411 aptamer‐functionalized/PAMAM dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer | |
| Yilmaz et al. | Polyphosphoesters: New trends in synthesis and drug delivery applications | |
| JP2012522055A5 (OSRAM) | ||
| Zhang et al. | Drug delivery systems for differential release in combination therapy | |
| Bugno et al. | Recent advances in targeted drug delivery approaches using dendritic polymers | |
| Jang et al. | Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression | |
| JP2018536655A5 (OSRAM) | ||
| JP2012532185A5 (OSRAM) | ||
| JP2013515745A5 (OSRAM) | ||
| JP2019521180A5 (OSRAM) | ||
| L. Beretta et al. | Engineering nanomedicines to overcome multidrug resistance in cancer therapy | |
| JP6038881B2 (ja) | 治療の方法及びそのために有用な剤 | |
| Ma et al. | Bioinspired spatiotemporal management toward RNA therapies | |
| Kubisa et al. | Star‐shaped copolymers with PLA–PEG arms and their potential applications as biomedical materials | |
| Yang et al. | Development of bioactive materials for glioblastoma therapy | |
| Choi et al. | Cumulative directional calcium gluing between phosphate and silicate: A facile, robust and biocompatible strategy for siRNA delivery by amine-free non-positive vector | |
| Fewell et al. | Treatment of disseminated ovarian cancer using nonviral interleukin‐12 gene therapy delivered intraperitoneally | |
| Karati et al. | A comprehensive review on targeted cancer therapy: new face of treatment approach | |
| Porello et al. | Advancing nucleic acid delivery through cationic polymer design: non-cationic building blocks from the toolbox | |
| Rana et al. | Recent advances in stimuli-responsive tailored nanogels for cancer therapy; from bench to personalized treatment | |
| Breusa et al. | Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer |